



TITLE:

Inhibition of Borna disease virus replication by an endogenous bornavirus-like element in the ground squirrel genome.

AUTHOR(S):

Fujino, Kan; Horie, Masayuki; Honda, Tomoyuki; Merriman, Dana K; Tomonaga, Keizo

CITATION:

Fujino, Kan ...[et al]. Inhibition of Borna disease virus replication by an endogenous bornavirus-like element in the ground squirrel genome.. Proceedings of the National Academy of Sciences of the United States of America 2014, 111(36): 13175-13180

ISSUE DATE:

2014-09-09

URL:

<http://hdl.handle.net/2433/191002>

RIGHT:

© 2014 National Academy of Sciences.; This is not the published version. Please cite only the published version.; この論文は出版社版でありません。引用の際には出版社版をご確認ご利用ください。

1 Inhibition of Borna disease virus replication by an endogenous bornavirus-like element
2 in the ground squirrel genome

3
4 Kan Fujino^{1,†}, Masayuki Horie^{1,§}, Tomoyuki Honda^{1,4}, Dana K. Merriman² and Keizo Tomonaga^{1,3,4*}

5
6 ¹Department of Viral Oncology, Institute for Virus Research, Kyoto University, Kyoto 606-8507,
7 Japan, ²Department of Biology and Microbiology, University of Wisconsin Oshkosh, Oshkosh, WI
8 54901-8630, USA. ³Department of Tumor Viruses, Graduate School of Medicine, Kyoto University,
9 Kyoto, Japan. ⁴Department of Mammalian Regulatory Network, Graduate School of Biostudies,
10 Kyoto University, Kyoto, Japan.

11
12 [†]Present address; Laboratory of Infectious Disease, School of Veterinary Medicine, Azabu University,
13 Fuchinobe, Chuo-ku, Sagamihara-shi, Kanagawa, 252-5201, Japan.

14 [§]Present address; Transboundary Animal Diseases Research Center, Joint Faculty of Veterinary Medicine,
15 Kagoshima University, 1-21-24 Korimoto, Kagoshima 890-0065, Japan.

16 *To whom correspondence should be addressed. Keizo Tomonaga: Department of Viral Oncology, Institute
17 for Virus Research, Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan. Tel:
18 +81-75-751-3997, Fax: +81-75-751-4000, E-mail: tomonaga@virus.kyoto-u.ac.jp

Animal genomes contain endogenous viral sequences, such as endogenous retroviruses and retrotransposons. Recently, we and others discovered that non-retroviral viruses also have been endogenized in many vertebrate genomes. Bornaviruses belong to the *Mononegavirales* and have left endogenous fragments, called endogenous bornavirus-like elements (EBLs), in the genomes of many mammals. The striking features of EBLs are that they contain relatively long open reading frames (ORFs) which have high sequence homology to the extant bornavirus proteins. Furthermore, some EBLs derived from bornavirus nucleoprotein (EBLNs) have been shown to be transcribed as mRNA and probably are translated into proteins. These features lead us to speculate that EBLs may function as cellular co-opted genes. An EBLN element in the thirteen-lined ground squirrel (*Ictidomys tridecemlineatus*) genome, itEBLN, encodes an ORF with 77% amino acid sequence identity to the current bornavirus N. In this study, we cloned itEBLN from the ground squirrel genome and investigated its involvement in Borna disease virus (BDV) replication. Interestingly, itEBLN, but not a human EBLN, co-localized with the viral factory in the nucleus and appeared to affect BDV polymerase activity by being incorporated into the viral ribonucleoprotein. Our data show that, as with certain endogenous retroviruses, itEBLN potentially may inhibit infection by related exogenous viruses in vivo.

KEYWORDS; Endogenous non-retroviral viruses, Bornavirus, Anti-viral immunity

Significance statement

Sequences derived from ancient viruses have been shown to make up a substantial part of animal genomes. Bornaviruses, a genus of non-segmented, negative-sense RNA virus, have also left their DNA copies in the genomes of quite a number of vertebrate lineages. Recent studies have demonstrated that some endogenous bornavirus elements (EBLs) may have acquired functions in their hosts as a result of exaptation. In this study, we show that protein encoded by an EBL in the thirteen-lined ground squirrel genome efficiently blocks infection and replication of extant bornavirus. This is the first report showing that endogenous elements derived from non-retroviral RNA viruses may have been co-opted for a new function of anti-viral defense in hosts.

body

Endogenous retroviruses have accumulated in the genomes of many organisms over evolutionary time and occupy about 8% of the human genome (1). Although almost all endogenous retroviruses in animal genomes appear to lack intact open reading frames (ORFs) and are not expressed in somatic tissues, some retain the potential to express mRNA and even produce the proteins they encode (2, 3). There is mounting evidence that expression of human endogenous retroviruses (HERVs) is associated with some autoimmune diseases, cancers and schizophrenia, as well as viral infections (4-6), suggesting that the induction of HERVs may be linked to immunological aberrations in the host. In addition, it has been reported that endogenous retroviruses have the ability to recombine with exogenous or other endogenous retroviruses to produce intact infectious viruses (7, 8). These observations indicate that the expression of endogenous retroviruses may cause deleterious consequences directly to the hosts.

On the other hand, recent studies have revealed clearly that endogenous retroviruses have been co-opted to play new and beneficial roles in their hosts (9, 10). For instance, in mammals, envelope genes from endogenous retroviruses are involved in the formation of the placenta during the fusion of syncytiotrophoblast cells (9, 11). In addition, a retroviral-like aspartic protease, skin aspartic protease, SASPase, is known to play a key role in determining the texture of skin by modulating the degree of hydration in mammals (12, 13). Furthermore, it has been known for decades that endogenous retrovirus-derived elements, such as Friend virus susceptibility 1 (Fv1) gene and endogenous fragments from Jaagsiekte sheep retrovirus (enJSRV), protect host cells from infection by exogenous retroviruses (10, 14, 15). These

lines of evidence suggest that evolution has favored persistence of endogenous retroviral elements that have the potential to protect their hosts against related viruses.

Recent advances in the availability of genomic sequences from many animal species, as well as the development of tools for sequence comparisons, have revealed that non-retroviral viruses also have endogenized in many mammalian species (16-18). Bornavirus, an enveloped, nonsegmented, negative-strand RNA virus in the order *Mononegavirales*, is unique among animal RNA viruses, not only because it replicates in the cell nucleus but also because it readily establishes a long-lasting persistent infection in the absence of overt cytopathogenesis (19). Although bornavirus does not integrate into the host genome during its replication cycle, interestingly, we and others found recently that DNA sequences derived from ancient bornaviruses are endogenized in the genomes of many vertebrate species, including humans (16, 17). The endogenous fragments of bornavirus in mammalian genomes originate predominantly from the region encoding the viral nucleoprotein (N), which encapsidates viral genomic RNA to form nucleocapsids, and we therefore designated them endogenous bornavirus-like nucleoproteins (EBLNs) (16).

In a previous study, we showed that EBLNs from the human and thirteen-lined ground squirrel (TLS) (*Ictidomys tridecemlineatus*) genomes, named hsEBLN and itEBLN, respectively, have significant sequence similarity to the N ORFs of extant mammalian bornaviruses, Borna disease virus (BDV). The elements, hsEBLN-1 and -2, which are located in chromosomes 10 and 3 of the human genome, respectively, encode ORFs with an overall 41% amino acid sequence identity to BDV N (16). itEBLN also has an intact ORF and shows approximately 77% amino acid sequence identity to N. Furthermore, it has been shown that

some hsEBLNs, including hsEBLN-1 and -2, are expressed as RNA and that a predicted mRNA transcript of itEBLN is provided by NCBI RefSeq (XM_005342477). Interestingly, we have found that long terminal repeats (LTR-1C and LTR-21B) from endogenous retroviruses exist in close proximity and upstream of itEBLN ORF (20). In fact, we could detect the predicted transcripts of itEBLN in several tissue samples from both breeding and wild-captured TLSs by RT-PCR (Supplementary Fig. S1). From these observations, it is tempting to speculate that EBLNs encode functional proteins as a consequence of exaptation or co-option by their hosts.

In this study, we cloned hsEBLN-1 and itEBLN sequences from the human and TLS genomes, respectively, to determine whether these EBLNs encode potentially functional proteins. We found that the protein encoded by itEBLN, but not hsEBLN-1, colocalizes with the viral factory in the nucleus and markedly decreases infection and the replication of exogenous BDV. Furthermore, the protein encoded by itEBLN appeared to be incorporated into the viral ribonucleoproteins (RNPs) in infected cells. These results suggest that, like some endogenous retroviruses, itEBLN has the potential as a co-opted gene in the host to inhibit infection by genetically related viruses.

RESULTS

Expression and reconstruction of EBLN elements from the human and ground squirrel genomes. To investigate the potential roles of the EBLN elements in the human and TLS genomes, we first amplified EBLN sequences from the genomic DNAs and cloned the

products into expression vectors. Although the expression of hsEBLN-1 and itEBLN has been predicted in previous studies (16, 18), the structure and transcription initiation sites of the EBLN RNAs have not been characterized. In this study, therefore, we cloned only the homologous regions to BDV N. To detect the expressed EBLN products, an HA-tag was fused to the N-terminus of the coding sequences. At first, we transfected the plasmids into human OL cells and investigated the expression of the reconstituted proteins by western blotting at 24 h posttransfection. As shown in Fig. 1A, expression of the recombinant proteins was detected as approximately 35 to 40 kDa products, indicating that the EBLNs may have the ability to stably express the proteins in mammalian cells. In addition, we carried out immunofluorescence assays to examine the subcellular localization of the proteins. As shown in Fig. 1B, while BDV N clearly localizes in the nucleus, itEBLN and hsEBLN-1 appear to be distributed predominantly in the cytoplasm of the transfected cells, probably because these proteins lack the nuclear localization signal (NLS), which is present in the N-terminus of BDV N (see Fig. 5).

Next, we transfected the EBLN plasmids into OL cells persistently infected with BDV. In a previous study, we demonstrated that BDV generates dot-like structures, called vSPOT (viral speckles of transcripts), in the nucleus (21). The vSPOT is the viral factory, in which essential events in the BDV replication cycle take place and could be the same structured nuclear bodies having the same function, as Joest-Degen inclusion bodies *in vivo* (22-24). Despite the lack of a nuclear localization activity, itEBLN was strongly redistributed to vSPOTs in the nucleus, as does N (Fig. 1C, arrowheads). On the other hand, hsEBLN-1 seemed to be not relocated in the infected cells. This observation suggests that itEBLN, but

not hsEBLN-1, may have the potential to interact with the viral components in the infected cells, leading to colocalization with vSPOT in the nucleus.

itEBLN inhibits BDV replication in persistently infected cells. In a previous study, Geib et al. (2003) revealed that transient expression of BDV P, but not N, inhibits viral replication (25) in Vero cells persistently infected with BDV. Therefore, we next investigated whether expression of hsEBLN-1 and itEBLN affects BDV replication in persistently infected cells. To evaluate viral transcription/replication, we measured the level of viral RNAs in cells transfected with the EBLN plasmids. Consistent with previous reports, transient expression of N in persistently infected OL cells did not exert any effect on BDV replication (Fig. 1D and 1E). In contrast, intriguingly, expression of itEBLN, but not hsEBLN-1, significantly reduced the levels of both viral genomic and mRNA at 48 h posttransfection (Fig. 1D and 1E). This result suggested that, unlike N, itEBLN could inhibit both the transcription and replication of BDV.

Expression of itEBLN confers resistance to exogenous BDV infection. Previous studies revealed that expression of BDV N protects cells from subsequent infection by BDV (25). Although the detailed mechanism of this resistance to superinfection has not been elucidated, it is assumed that an early step of BDV infection, such as nuclear transport of viral RNP, intranuclear dissemination or initiation of viral replication, may be interfered with by the overexpression of the viral nucleocapsid component (25). To determine whether itEBLN can also affect BDV infection, we established OL cell lines stably expressing itEBLN or

162 hsEBLN-1. In this experiment, we also generated a plasmid, pNL-itEBLN, in which itEBLN
163 is fused with the NLS of BDV N at the N-terminus (Fig. 2A), in order to investigate the effect
164 of nuclear localization of the protein. As for N, the product of pNL-itEBLN clearly localized
165 in the nuclei of transiently transfected cells (Fig. 2B). We then infected the cell lines with
166 cell-free virions of recombinant BDV (rBDV) expressing GFP, rBDV P/M-GFP, with an
167 M.O.I. of 0.1 and monitored the propagation of GFP for at least 3 weeks. As shown in Fig. 2C
168 and 2D, the expression of itEBLN and NL-itEBLN, but not hsEBLN-1, nearly completely
169 protects the cells against BDV infection for the observation period, as does N, suggesting that
170 itEBLN protects against BDV infection in the nucleus

171 We next performed cocultivation experiments using the EBLN-expressing OL cell lines
172 and Vero cells persistently infected with rBDV P/M-GFP, to investigate whether itEBLN can
173 also inhibit the cell-to-cell spread of the infection, which is presumably the main route of
174 BDV transmission. Repeated experiments revealed that, despite incomplete protection of the
175 cells expressing N, itEBLN constructs were almost completely resistant to virus infection (Fig.
176 3A and 3B). This indicated that itEBLN could have a strong inhibitory effect on BDV
177 infection, even following cell-to-cell transmission. To exclude the possibility that the NLS
178 region (amino acids 1 to 38) of BDV N in the constructs has an effect on BDV replication, we
179 also conducted the experiments using two different plasmids, pNLsv-itEBLN and
180 pNL-DsRed, in which itEBLN and DsRed were fused with SV40 and BDV N NLS at the
181 N-terminus, respectively (Supplementary Fig. S2). The results in Supplementary Fig. S3 show
182 that the NLS region of N is not involved in the inhibitory effect of NL-itEBLN on BDV
183 replication.

184

185 **Incorporation of itEBLN into BDV RNP.** The results shown above suggest the
186 possibility that the itEBLN protein may be directly incorporated into BDV RNP, resulting in
187 inhibition of viral replication. To test this possibility, we performed an immunoprecipitation
188 analysis using BDV-infected cells transfected with the EBLN plasmids. At 24 h
189 posttransfection, the cell extracts were immunoprecipitated with anti-HA antibody and the
190 viral RNP components were detected by western blotting and RT-PCR. As shown in Fig. 4A,
191 BDV genomic RNA, as well as BDV P, was clearly precipitated with itEBLN and N, whereas
192 hsEBLN-1 seemed not to interact with BDV RNP in the cells. This observation revealed that
193 itEBLN may be efficiently incorporated into the viral RNP in infected cells.

194

195 **itEBLN inhibits BDV polymerase activity in a minireplicon system.** We next
196 determined whether itEBLNs can directly affect the polymerase activity of BDV. To this end,
197 we used a minireplicon system of BDV, which synthesizes recombinant BDV nucleocapsids
198 containing an artificial, minigenome reporter RNA, following transfection of expression
199 plasmids encoding BDV N, P, L, and the minigenome (26). We carried out the minireplicon
200 assay in the presence or absence of plasmids expressing itEBLN. Consistent with previous
201 observation (26), the viral polymerase activity was strongly inhibited when BDV X was
202 cotransfected with the minireplicon constructs (Fig. 4B). Interestingly, despite that BDV N
203 could not inhibit the polymerase activity of the minireplicon, all of the itEBLN constructs,
204 including itEBLN-M2, which is translated from the AUG codon at amino acid position 132 in
205 the itEBLN sequence (see Fig. 5), efficiently decreased the polymerase activity in the system

(Fig. 4B). Altogether, these results suggest that itEBLN acts as a dominant negative inhibitor of N by being incorporated into the viral RNP.

The putative tetramer and RNA interaction domains of BDV N are conserved in itEBLN.

Previous studies revealed that BDV N contains several signal sequences, including the NLS and nuclear export signal (NES), and putative P binding sites (27-29). Furthermore, structural studies of BDV N determined the amino acids essential for homotetramer formation and interaction with viral RNA (30, 31). To predict the function of itEBLN as a dominant negative inhibitor of N, we aligned the amino acid sequences of BDV N and itEBLN. As shown in Fig. 5, BDV N contains an NLS in the N-terminal region, whereas itEBLN lacks a homologous sequence in that region. On the other hand, putative binding sites for P (PBS-1 and -2) seem to be highly conserved between itEBLN and BDV N (Fig. 5). In addition, the sequences predicted to be involved in tetramerization of BDV N also seem to be conserved in the sequence of itEBLN, with the exception of the sequence in the N-terminus of BDV N (Fig. 5, asterisks). Furthermore, we also found that the corresponding residues essential for interaction with the viral RNA (K164, R165, K242 and R297) (Fig. 5, arrowheads) are well conserved in itEBLN. A structural model based on BDV N also revealed that the regions surrounding the RNA interaction sites are also conserved in itEBLN (Supplementary Fig. S4), suggesting that itEBLN may retain the ability to form nucleocapsids with BDV N.

DISCUSSION

In this study, we showed that the protein expressed from an endogenous bornavirus fragment from the TLS genome, itEBLN, is incorporated into BDV RNPs and inhibits BDV replication. This conclusion is supported by the following observations: first, we found that the itEBLN protein was colocalized with the viral factory of BDV in the nucleus. Second, the expression of this protein markedly reduced the replication level of BDV in persistently infected cells. Furthermore, the cells stably expressing the itEBLN protein were completely resistant to infection by exogenous BDV through both the cell-free and cell-to-cell routes. Third, we showed that the itEBLN protein can precipitate BDV RNP components, including viral genomic RNA, in infected cells. Finally, co-expression of itEBLN reduced BDV polymerase activity using the minireplicon system. To our knowledge, this is the first report that an endogenous, non-retroviral virus efficiently inhibits infection by the related exogenous virus.

In this study, we employed an overexpression system of recombinant itEBLN with human cell culture systems. Thus, in order to demonstrate the host-specific exaptation of itEBLN, it would be necessary to investigate whether TLSs actually exhibit resistance to BDV infection. At present, however, we could neither find any available cultured cells of TLSs nor establish experimental infection using TLSs. On the other hand, we could detect the expression of predicted mRNA of itEBLN in tissue samples from both breeding and wild-captured TLSs by RT-PCR (Supplemental Figure S1A and B). The immunoblot analysis using a BDV N-specific polyclonal antibody showed only a faint band at the predicted size in the heart samples (Supplemental Figure S1C). Although the expression of itEBLN protein remained obscure due to the specificity of the antibody, given that the itEBLN mRNAs are efficiently translated into the protein in the squirrel cells, itEBLN may protect BDV infection

250 in vivo. We will continue to make an effort to establish infection systems of TLSs with BDV.

251 Our results showed that the expression of itEBLN not only reduces viral replication but
252 also blocks de novo BDV infection. Immunofluorescence and immunoprecipitation assays
253 indicated that the itEBLN protein interacted efficiently with BDV RNP in the infected cells.
254 Among the RNP components, the most likely candidate is the N protein, because BDV N is
255 known to tightly assemble as a homotetramer (30). BDV N forms the nucleocapsid, which
256 serves as the template for RNA synthesis with the L and P proteins (31, 32), strongly
257 suggesting that itEBLN participates in heteromultimerization with BDV N. It has been
258 determined that the residues predicted to be important for tetramer formation by N are located
259 in the N- and C-termini of the protein (Fig. 5) (30). An amino acid comparison between the
260 itEBLN protein and BDV N revealed that the identity between BDV N and itEBLN may be
261 sufficient to permit heteromultimerization. It is highly likely, therefore, that the itEBLN
262 protein efficiently co-assembles with BDV N into viral nucleocapsids in infected cells. In a
263 previous study, Geib et al. (25) demonstrated that transient expression of recombinant N in
264 BDV persistently infected cells does not inhibit BDV replication, even though the transduced
265 N was colocalized with the viral factory in the nucleus. This observation was also confirmed
266 in our experiments shown in Fig. 1, suggesting that the itEBLN may act like a dominant
267 negative mutant of N in the viral nucleocapsids and exert a deleterious effect on the viral
268 replication. In fact, a numbers of substitutions, especially at the N-terminus, were found in the
269 itEBLN sequence (Fig. 5). Such heterogeneity might destabilize tetramer formation or the
270 interaction with viral RNAs, leading to inhibition of viral polymerase activity.

271 Alternatively, it may be possible that the itEBLN protein directly interacts with P and

inhibits the functions of P. In fact, the sequences corresponding to the P-binding sites in N have been shown to be well conserved in itEBLN. P plays important roles in viral replication, as a viral polymerase cofactor and in nucleocytoplasmic shuttling of the viral nucleocapsid (32-34). Although the intracellular distribution of P seems to be not altered by overexpression of itEBLN in the cells (Fig. 1C), the interaction between P and itEBLN may affect the dynamics of P in the infected cells. Furthermore, we previously demonstrated that expression of P regulates the translation efficiency of BDV X, which is a negative regulator of BDV polymerase (35). Thus, it may be also possible that their interaction affects the translation efficiency of X, resulting in the inhibition of polymerase activity of BDV. Together, it is conceivable that the effect of itEBLN on BDV replication may be multifaceted, via interaction with both N and P. Further experiments should be necessary to understand the mechanism of the inhibitory effect of itEBLN on BDV replication.

Our results may reveal an intriguing strategy for inhibition of exogenous virus infection by endogenous viral fragments. Previous studies clearly demonstrated that endogenous viral products are efficiently interacted into the capsids of incoming, genetically related viruses, resulting in inhibition of viral replication. A well-studied example is the Fv1 gene in mice. Fv1 originated from the *gag* gene of an ancient retrovirus, which was endogenized several million years ago into the genome of a common ancestor of mice and is known to restrict infection by specific strains of MLV (14, 36). Although the amino acid sequence of Fv1 is distant from the restricted MLVs, recent studies clearly indicate that direct interaction of Fv1 with the capsid protein of MLV induces the anti-MLV function of Fv1 (37). Another instance is the enJSRV. This endogenous virus is known to inhibit exogenous JSRV infection by two

different mechanisms (38). First, the envelope protein encoded by enJSRVs is expressed and binds to the cellular receptors used by JSRV (39). On the other hand, the Gag protein expressed by enJSRVs is also known to have deleterious effects on the replication of exogenous JSRV (15). A misfolded Gag protein of enJSRVs co-assembles with JSRV Gag and forms chimeric viral capsids, which are degraded by the proteasome system of the infected cells (40). In addition, Monde et al. have recently demonstrated that the Gag proteins of an endogenous betaretrovirus co-assemble with a distinct retrovirus, HIV-1, Gag protein to modulate the late phase of HIV-1 replication (41). Together with our observation that itEBLN also has the ability to form nucleocapsids with BDV N, interaction of endogenous viral products into the capsids or nucleocapsids of incoming exogenous viruses may be an effective way to regulate virus infections.

Recent studies have demonstrated that the human genome contains many intrinsic factors that prevent viral infection (10, 42). Such factors could be acquired during evolution as consequences of the battle between viruses and their hosts. There is no doubt that the arms race between the host and virus has affected the evolution of both. In addition to the sophistication of the immune system, host organisms must have acquired many genes to overcome infection by pathogens over many generations of evolution. Exaptation is the co-opting of exogenous sequences as new genes, with functions distinct from their original purpose, into the genome (10, 43). The co-option of endogenous retroviruses as anti-viral factors is a good example of such exaptation. Until now, retroviruses were considered to be the only virus family that has been co-opted as new functional genes in the host genomes. Our results strongly suggest that exaptation by non-retroviral viral genes may have occurred

during the co-evolution of bornaviruses and their hosts.

At present, some EBLNs from human and non-human primate genomes, including hsEBLN-1 and hsEBLN-2, have been shown to express RNAs that potentially encode proteins (16, 44). Although we could not demonstrate an inhibitory effect of the hsEBLN-1 protein on the BDV replication, the possibilities that hsEBLN-1 plays roles in the cellular environment or acts at the level of RNA remain to be elucidated. On the other hand, hsEBLN-2 has been shown to express protein in human cells (44). A recent study also revealed that hsEBLN-2 is a candidate gene of the recurrent 3p12-p14 loss in cervical cancer and could be a novel tumour suppressor in cervical cancer (45). The human EBLNs are considered to have been generated 40 to 45 million years ago. Nevertheless, relatively long ORFs are conserved in these elements, especially hsEBLN-1 and -2, and these have a high level of amino acid identity with the N protein of current bornaviruses (16). These observations suggest the intriguing possibility that hsEBLN-1 and -2 have been adapted during evolution with new functions in the host cells. We are currently working on understanding the co-opted roles of the EBLNs, as well as other endogenous non-retroviral elements, in mammalian genomes. These studies could provide new insights into the co-evolution and between viruses and their hosts and the co-option of new genes in hosts following infection by exogenous viruses.

Materials and Methods

Cells. OL (human oligodendroglioma) and Vero cell lines were cultured in Dulbecco's

modified Eagle's medium (DMEM)-high glucose (4.5%) supplemented with 5% fetal bovine serum (FBS) and 4 mM glutamine. HEK293T cells were cultured in DMEM-low glucose (1.0%) supplemented with 10% FBS. OL cells persistently infected with BDV strain huP2br (OL/BDV) were cultured using the same conditions as the parental cell line. The cell lines stably expressing hsEBLN-1, itEBLN or BDV N were established by the limiting dilution and maintained in culture medium with Zeocin (Invitrogen) or G418 (Invitrogen).

Virus Infection. OL cell lines stably expressing the EBLN constructs were infected with cell-free rBDV P/M-GFP (46) virions at an M.O.I of 0.1. After absorption for 1 h, the cells were washed with phosphate-buffered saline (PBS) and passaged within 2 or 3 days. In addition, the OL cell lines were cocultured with Vero cells persistently infected with rBDV P/M-GFP. Three days after the co-cultivation, the cells were treated by Zeocin or G418 to eliminate the Vero cells. The infection rates of the cells were determined by measuring GFP expression using a FACSCalibur flow cytometer (BD Biosciences) or Tali Image-Based Cytometer (Invitrogen).

Minireplicon Assay. Minireplicon assays were carried out according to Yanai et al. (26). Briefly, HEK293T cells were seeded in 12-well plates and transfected with expression plasmids of BDV N (0.1 µg), P (0.01 µg), RNA-dependent RNA polymerase (L) (0.1 µg) and Pol II-driven minigenome plasmids (0.1 µg), with or without EBLN and BDV X expression plasmids (0.5 µg), using Lipofectamine 2000 (Invitrogen). 48 h later, the cells were lysed and cell lysates were prepared for chloramphenicol acetyltransferase (CAT) assay.

360

361 **Acknowledgements**

362 This study was supported in part by Funding Program for Next Generation World-Leading
363 Researchers (NEXT program) and a Grant-in-Aid for Scientific Research (A) (26253027)
364 from Japan Society for the Promotion of Science (JSPS) (KT), a Grant-in-Aid for Scientific
365 Research on Innovative Areas (24115709 and 25115508) (TH) from the Ministry of Education,
366 Culture, Science, Sports and Technology (MEXT) of Japan, and grants from Takeda Science
367 Foundation (KT).

368

369 **References**

- 370
- 371 1. Bock M & Stoye JP (2000) Endogenous retroviruses and the human germline. *Curr Opin*
372 *Genet Dev* 10(6): 651-655.
- 373 2. Bannert N & Kurth R. (2004) Retroelements and the human genome: new perspectives
374 on an old relation. *Proc Natl Acad Sci USA* 101(Suppl 2):14572-14579.
- 375 3. Stoye JP (2012) Studies of endogenous retroviruses reveal a continuing evolutionary saga.
376 *Nat Rev Microbiol* 10(6): 395-406.
- 377 4. Krieg AM, Gourley MF & Perl A (1992) Endogenous retroviruses: Potential etiologic
378 agents in autoimmunity. *FASEB J* 6(8): 2537-2544.
- 379 5. Singh S, Kaye S, Gore ME, McClure MO & Bunker CB (2009) The role of human
380 endogenous retroviruses in melanoma. *Br J Dermatol* 161(6): 1225-1231.
- 381 6. Christensen T (2010) HERVs in neuropathogenesis. *J Neuroimmune Pharmacol* 5(3):
382 326-335.
- 383 7. Evans LH, et al (2006) In vivo interactions of ecotropic and polytropic murine leukemia
384 viruses in mixed retrovirus infections. *J Virol* 80(10): 4748-4757.
- 385 8. Roy-Burman P (1995) Endogenous env elements: Partners in generation of pathogenic
386 feline leukemia viruses. *Virus Genes* 11(2-3): 147-161.
- 387 9. Mi S, et al (2000) Syncytin is a captive retroviral envelope protein involved in human
388 placental morphogenesis. *Nature* 403(6771): 785-789.
- 389 10. Aswad A & Katzourakis A (2012) Paleovirology and virally derived immunity. *Trends*
390 *Ecol Evol* 27(11): 627-636.

- 391 11. Dupressoir A, et al (2005) Syncytin-A and syncytin-B, two fusogenic placenta-specific
392 murine envelope genes of retroviral origin conserved in muridae. *Proc Natl Acad Sci*
393 USA 102(3): 725-730.
- 394 12. Bernard D, et al (2005) Identification and characterization of a novel retroviral-like
395 aspartic protease specifically expressed in human epidermis. *J Invest Dermatol* 125(2):
396 278-287.
- 397 13. Matsui T, et al (2011) SASPase regulates stratum corneum hydration through
398 profilaggrin-to-filaggrin processing. *EMBO Mol Med* 3(6): 320-333.
- 399 14. Stoye JP (1998) Fv1, the mouse retrovirus resistance gene. *Rev Sci Tech* 17(1): 269-277.
- 400 15. Mura M, et al (2004) Late viral interference induced by transdominant gag of an
401 endogenous retrovirus. *Proc Natl Acad Sci USA* 101(30): 11117-11122.
- 402 16. Horie M, et al (2010) Endogenous non-retroviral RNA virus elements in mammalian
403 genomes. *Nature* 463(7277): 84-87.
- 404 17. Belyi VA, Levine AJ & Skalka AM (2010) Unexpected inheritance: Multiple integrations
405 of ancient bornavirus and ebolavirus/marburgvirus sequences in vertebrate genomes.
406 *PLoS Pathog* 6(7): e1001030.
- 407 18. Katzourakis A & Gifford RJ (2010) Endogenous viral elements in animal genomes. *PLoS*
408 *Genet* 6(11): e1001191.
- 409 19. Tomonaga K, Kobayashi T & Ikuta K (2002) Molecular and cellular biology of borna
410 disease virus infection. *Microbes Infect* 4(4): 491-500.
- 411 20. Suzuki Y, Kobayashi Y, Horie M & Tomonaga K Origin of endogenous bornavirus-like
412 nucleoprotein elements in thirteen-lined ground squirrels. *Genes Genet Syst* (in press)

- 413 21. Matsumoto Y, et al (2012) Bornavirus closely associates and segregates with host
414 chromosomes to ensure persistent intranuclear infection. *Cell Host Microbe* 11(5):
415 492-503.
- 416 22. Schneider U, Naegele M, Staeheli P & Schwemmle M (2003) Active borna disease virus
417 polymerase complex requires a distinct nucleoprotein-to-phosphoprotein ratio but no viral
418 X protein. *J Virol* 77(21): 11781-11789.
- 419 23. Chase G, et al (2007) Borna disease virus matrix protein is an integral component of the
420 viral ribonucleoprotein complex that does not interfere with polymerase activity. *J Virol*
421 81(2): 743-749.
- 422 24. Sasaki S & Ludwig H (1993) In borna disease virus infected rabbit neurons 100 nm
423 particle structures accumulate at areas of Joest-Degen inclusion bodies. *Zentralbl*
424 *Veterinarmed B* 40(4): 291-297.
- 425 25. Geib T, et al (2003) Selective virus resistance conferred by expression of borna disease
426 virus nucleocapsid components. *J Virol* 77(7): 4283-4290.
- 427 26. Yanai H, et al (2006) Development of a novel borna disease virus reverse genetics system
428 using RNA polymerase II promoter and SV40 nuclear import signal. *Microbes Infect*
429 8(6): 1522-1529.
- 430 27. Kobayashi T, et al (1998) Nuclear targeting activity associated with the amino terminal
431 region of the borna disease virus nucleoprotein. *Virology* 243(1): 188-197.
- 432 28. Berg M, Ehrenborg C, Blomberg J, Pipkorn R & Berg AL (1998) Two domains of the
433 borna disease virus p40 protein are required for interaction with the p23 protein. *J Gen*
434 *Virol* 79 (12): 2957-2963.

- 435 29. Kobayashi T, et al (2001) Borna disease virus nucleoprotein requires both nuclear
436 localization and export activities for viral nucleocytoplasmic shuttling. *J Virol* 75(7):
437 3404-3412.
- 438 30. Rudolph MG, et al (2003) Crystal structure of the borna disease virus nucleoprotein.
439 *Structure* 11(10): 1219-1226.
- 440 31. Hock M, et al (2010) RNA induced polymerization of the borna disease virus
441 nucleoprotein. *Virology* 397(1): 64-72.
- 442 32. Schwemmle M, et al (1998) Interactions of the borna disease virus P, N, and X proteins
443 and their functional implications. *J Biol Chem* 273(15): 9007-9012.
- 444 33. Schwemmle M, Jehle C, Shoemaker T & Lipkin WI (1999) Characterization of the major
445 nuclear localization signal of the borna disease virus phosphoprotein. *J Gen Virol* 80(1):
446 97-100.
- 447 34. Yanai H, et al (2006) A methionine-rich domain mediates CRM1-dependent nuclear
448 export activity of borna disease virus phosphoprotein. *J Virol* 80(3): 1121-1129.
- 449 35. Watanabe Y, Ohtaki N, Hayashi Y, Ikuta K & Tomonaga K (2009) Autogenous
450 translational regulation of the borna disease virus negative control factor X from
451 polycistronic mRNA using host RNA helicases. *PLoS Pathog* 5(11): e1000654.
- 452 36. Best S, Le Tissier P, Towers G & Stoye JP (1996) Positional cloning of the mouse
453 retrovirus restriction gene Fv1. *Nature* 382(6594): 826-829.
- 454 37. Hilditch L, et al (2011) Ordered assembly of murine leukemia virus capsid protein on
455 lipid nanotubes directs specific binding by the restriction factor, Fv1. *Proc Natl Acad Sci*
456 *USA* 108(14): 5771-5776.

- 457 38. Arnaud F, Varela M, Spencer TE & Palmarini M (2008) Coevolution of endogenous
458 betaretroviruses of sheep and their host. *Cell Mol Life Sci* 65(21): 3422-3432.
- 459 39. Spencer TE, Mura M, Gray CA, Griebel PJ & Palmarini M (2003) Receptor usage and
460 fetal expression of ovine endogenous betaretroviruses: Implications for coevolution of
461 endogenous and exogenous retroviruses. *J Virol* 77(1): 749-753.
- 462 40. Arnaud F, Murcia PR & Palmarini M (2007) Mechanisms of late restriction induced by
463 an endogenous retrovirus. *J Virol* 81(20): 11441-11451.
- 464 41. Monde K, Contreras-Galindo R, Kaplan MH, Markovitz DM & Ono A (2012) Human
465 endogenous retrovirus K gag coassembles with HIV-1 gag and reduces the release
466 efficiency and infectivity of HIV-1. *J Virol* 86(20): 11194-11208.
- 467 42. Bieniasz PD (2004) Intrinsic immunity: A front-line defense against viral attack. *Nat*
468 *Immunol* 5(11): 1109-1115.
- 469 43. Dupressoir A, Lavalie C & Heidmann T (2012) From ancestral infectious retroviruses to
470 bona fide cellular genes: Role of the captured syncytins in placentation. *Placenta* 33(9):
471 663-671.
- 472 44. Ewing RM, et al (2007) Large-scale mapping of human protein-protein interactions by
473 mass spectrometry. *Mol Syst Biol* 3: 89.
- 474 45. Lando M, et al (2013) Identification of eight candidate target genes of the recurrent
475 3p12-p14 loss in cervical cancer by integrative genomic profiling. *J Pathol* 230(1): 59-69.
- 476 46. Daito T, et al (2011) A novel borna disease virus vector system that stably expresses
477 foreign proteins from an intercistronic noncoding region. *J Virol* 85(23): 12170-12178.

478

479

Figure legends

Fig. 1. Expression of itEBLN inhibits BDV replication in transfected human cells. (A)

Expression of recombinant EBLN proteins in transiently transfected OL cells. The HA-fused itEBLN, hsEBLN-1 and BDV N constructs were transfected into OL cells and the expressed proteins were detected by western blotting using anti-HA antibody. (B and C) Subcellular localization of recombinant EBLNs in transfected cells. The expression plasmids were transfected into uninfected (B) and OL cells persistently infected with BDV (C), and the distributions of EBLN proteins and BDV P were visualized by immunofluorescence assay with anti-HA (red) and anti-P (green) antibodies, respectively. Cells were counterstained with DAPI. Scale bar, 10 μ m. Arrowheads in (C) indicate bornavirus viral factories, vSPOT. (D and E) Expression of itEBLN decreases the level of BDV RNAs in persistently infected cells. Forty-eight hour after transfection of the indicated constructs, the amounts of BDV genomic RNA (D) and mRNA (E) were quantified by real-time RT-PCR. Empty indicates the cells transfected with an empty vector. The values are presented as the mean \pm SE of three independent experiments. Statistical significance was analyzed by the two-tailed t test. * p < 0.05, ** p < 0.01.

Fig. 2. Expression of itEBLN in human cells inhibits BDV infection. (A) Schematic

representations of the recombinant proteins of BDV N and itEBLN. An expression plasmid, pNL-itEBLN, was generated by fusing the NLS of BDV N (amino acids 1 to 38) to the N-terminus of itEBLN ORF. (B) Subcellular localization of NL-itEBLN in the transiently

transfected BDV/OL cells. Scale bar, 10 μ m. (C) OL cells stably expressing pHA-N, pitEBLN, pNL-itEBLN and phsEBLN-1 were inoculated with cell-free rBDV expressing GFP at an M.O.I. of 0.1. GFP expression was monitored by fluorescence microscopy. The cells were photographed 4 days after infection. (D) The percentage of GFP-expressing cells was monitored over a period of 35 days.

Fig. 3. Expression of itEBLN protects against cell-to-cell transmission of BDV. (A) OL cells stably expressing pHA-N, pitEBLN, pNL-itEBLN and phsEBLN-1 were co-cultured with Vero cells persistently infected with rBDV P/M-GFP. Three days after co-cultivation, the cells were treated with Zeocin or G418 to eliminate the Vero cells. The GFP expression was monitored by fluorescence microscopy. The cells were photographed 24 days after co-cultivation. (B) The percentage of GFP-expressing cells was monitored over a period of 24 days.


Fig. 4. itEBLN is incorporated into viral RNPs and affects BDV polymerase activity. (A) Immunoprecipitation analysis of itEBLN in OL/BDV cells. OL cells persistently infected with BDV were transfected with the indicated constructs, lysed twenty-four hour after transfection and immunoprecipitated with anti-HA antibody. Empty indicates empty vector (pcDNA3)-transfected cells. BDV P was detected by anti-BDV P antibody (arrow). The asterisk indicates non-specific bands detected in all cells. BDV genomic RNA was detected by RT-PCR using primers specific for the genome sense RNA within the BDV P region. (B) Expression of itEBLN inhibits BDV polymerase activity in a minireplicon assay. HEK293T


cells were co-transfected with a set of BDV minigenome plasmids and the expression constructs for itEBLN, hsEBLN-1, BDV N and BDV X. Forty-eight hours after transfection, the cells were lysed and subjected to CAT assays. The CAT activities are expressed as the ratio relative to empty vector-cotransfected cells (Empty). The values are the mean \pm SE of three independent experiments. Statistical significance was analyzed by the two-tailed t test.

** $p < 0.01$

Fig. 5. Amino acid sequence alignment of BDV N and itEBLN. The identical amino acids in BDV N and itEBLN are shown by blue shading. The sequences of the NLS and NES and two P-binding sites (PBS-1/-2) are indicated. Arrowheads indicate the predicted amino acids residues essential for interaction with the viral RNA. The asterisks between the sequences indicate the residues predicted to be involved in the tetramerization of BDV N. Red and blue asterisks indicate residues interacting with the preceding and following crystallographic neighbors to form the tetramer, respectively. The initiation site of itEBLN-M2 is also indicated.

Fig. 1








Fig. 4






Fig. 5

